{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:46:57Z","timestamp":1762955217098},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Emerg Med"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1865-1380-6-25","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T08:14:03Z","timestamp":1373962443000},"source":"Crossref","is-referenced-by-count":4,"title":["Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism"],"prefix":"10.1186","volume":"6","author":[{"given":"Patrick","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isma\u00efl","family":"Elalamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Danchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,16]]},"reference":[{"key":"144_CR1","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1378\/chest.116.4.903","volume":"116","author":"P Girard","year":"1999","unstructured":"Girard P, Musset D, Parent F, Maitre S, Phlippoteau C, Simonneau G: High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest 1999, 116: 903\u2013908. 10.1378\/chest.116.4.903","journal-title":"Chest"},{"key":"144_CR2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1056\/NEJMra072753","volume":"358","author":"VF Tapson","year":"2008","unstructured":"Tapson VF: Acute pulmonary embolism. N Engl J Med 2008, 358: 1037\u20131052. 10.1056\/NEJMra072753","journal-title":"N Engl J Med"},{"key":"144_CR3","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1093\/eurheartj\/ehn475","volume":"29","author":"A Torbicki","year":"2008","unstructured":"Torbicki A, Perrier A, Konstantinides S, Agnelli G, Gali\u00e8 N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, et al.: Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008, 29: 2276\u20132315.","journal-title":"Eur Heart J"},{"key":"144_CR4","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1161\/CIRCULATIONAHA.109.853119","volume":"121","author":"JW Eikelboom","year":"2010","unstructured":"Eikelboom JW, Weitz JI: New anticoagulants. Circulation 2010, 121: 1523\u20131532. 10.1161\/CIRCULATIONAHA.109.853119","journal-title":"Circulation"},{"key":"144_CR5","volume-title":"Xarelto\u00ae (rivaroxaban) Summary of Product Characteristics","author":"AG Bayer Pharma","year":"2013","unstructured":"Bayer Pharma AG: Xarelto\u00ae (rivaroxaban) Summary of Product Characteristics. 2013. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf"},{"key":"144_CR6","volume-title":"Xarelto\u00ae (rivaroxaban) Prescribing Information","author":"Janssen Pharmaceuticals Inc","year":"2013","unstructured":"Janssen Pharmaceuticals Inc: Xarelto\u00ae (rivaroxaban) Prescribing Information. 2013. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022406s004lbl.pdf"},{"key":"144_CR7","doi-asserted-by":"publisher","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, et al.: Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141: e419S-e494S. 10.1378\/chest.11-2301","journal-title":"Chest"},{"key":"144_CR8","doi-asserted-by":"publisher","first-page":"e24S","DOI":"10.1378\/chest.11-2291","volume":"141","author":"DA Garcia","year":"2012","unstructured":"Garcia DA, Baglin TP, Weitz JI, Samama MM: Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141: e24S-e43S. 10.1378\/chest.11-2291","journal-title":"Chest"},{"key":"144_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJM199709043371001","volume":"337","author":"The Columbus Investigators","year":"1997","unstructured":"The Columbus Investigators: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997, 337: 657\u2013662.","journal-title":"N Engl J Med"},{"key":"144_CR10","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMe038112","volume":"349","author":"HR B\u00fcller","year":"2003","unstructured":"B\u00fcller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, et al.: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003, 349: 1695\u20131702.","journal-title":"N Engl J Med"},{"key":"144_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","volume":"140","author":"HR B\u00fcller","year":"2004","unstructured":"B\u00fcller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, et al.: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004, 140: 867\u2013873. 10.7326\/0003-4819-140-11-200406010-00007","journal-title":"Ann Intern Med"},{"key":"144_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"The EINSTEIN\u2013PE Investigators","year":"2012","unstructured":"The EINSTEIN\u2013PE Investigators: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366: 1287\u20131297.","journal-title":"N Engl J Med"},{"key":"144_CR13","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"The EINSTEIN Investigators","year":"2010","unstructured":"The EINSTEIN Investigators: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363: 2499\u20132510.","journal-title":"N Engl J Med"},{"key":"144_CR14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1160\/TH07-03-0212","volume":"98","author":"AT Cohen","year":"2007","unstructured":"Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, et al.: Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007, 98: 756\u2013764.","journal-title":"Thromb Haemost"},{"key":"144_CR15","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","volume":"112","author":"HR B\u00fcller","year":"2008","unstructured":"B\u00fcller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A, et al.: A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study. Blood 2008, 112: 2242\u20132247. 10.1182\/blood-2008-05-160143","journal-title":"Blood"},{"key":"144_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","volume":"116","author":"G Agnelli","year":"2007","unstructured":"Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S, ODIXa-DVT Study Investigators: Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59\u20137939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59\u20137939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007, 116: 180\u2013187. 10.1161\/CIRCULATIONAHA.106.668020","journal-title":"Circulation"},{"key":"144_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jama.293.6.681","volume":"293","author":"JN Fiessinger","year":"2005","unstructured":"Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundstr\u00f6m T, Berkowitz SD, Nystr\u00f6m P, Thors\u00e9n M, et al.: Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005, 293: 681\u2013689. 10.1001\/jama.293.6.681","journal-title":"JAMA"},{"key":"144_CR18","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1056\/NEJMoa064247","volume":"357","author":"HR B\u00fcller","year":"2007","unstructured":"B\u00fcller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, van Gogh Investigators, et al.: Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007, 357: 1094\u20131104.","journal-title":"N Engl J Med"},{"key":"144_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","volume":"50","author":"W Mueck","year":"2011","unstructured":"Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F: Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011, 50: 675\u2013686. 10.2165\/11595320-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"144_CR20","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, for the RE-COVER Study Group: Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361: 2342\u20132352. 10.1056\/NEJMoa0906598","journal-title":"N Engl J Med"},{"key":"144_CR21","first-page":"Abstract 205","volume":"118","author":"S Schulman","year":"2011","unstructured":"Schulman S, Kakkar AK, Schellong SM, Goldhaber SZ, Eriksson H, Mismetti P, Christiansen AV, Schnee J, Kearon C: A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II) [abstract]. Blood (ASH Annual Meeting Abstracts) 2011, 118: Abstract 205.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"144_CR22","doi-asserted-by":"publisher","first-page":"e7498","DOI":"10.1136\/bmj.e7498","volume":"345","author":"BD Fox","year":"2012","unstructured":"Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A: Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012, 345: e7498. 10.1136\/bmj.e7498","journal-title":"BMJ"},{"key":"144_CR23","volume-title":"Clexane\u00ae and Clexane Forte\u00ae (enoxaparin sodium)","author":"sanofi-aventis new zealand limited","year":"2010","unstructured":"sanofi-aventis new zealand limited: Clexane\u00ae and Clexane Forte\u00ae (enoxaparin sodium). 2010. \n                    http:\/\/www.medsafe.govt.nz\/profs\/datasheet\/c\/clexaneinj.pdf"},{"key":"144_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","volume":"127","author":"MM Samama","year":"2011","unstructured":"Samama MM: The mechanism of action of rivaroxaban \u2013 an oral, direct factor Xa inhibitor \u2013 compared with other anticoagulants. Thromb Res 2011, 127: 497\u2013504. 10.1016\/j.thromres.2010.09.008","journal-title":"Thromb Res"},{"key":"144_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","volume":"30","author":"E Perzborn","year":"2010","unstructured":"Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V: Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010, 30: 376\u2013381. 10.1161\/ATVBAHA.110.202978","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"144_CR26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/eurheartj\/ehs408","volume":"34","author":"DM Siegal","year":"2013","unstructured":"Siegal DM, Crowther MA: Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2013, 34: 489\u2013498. 10.1093\/eurheartj\/ehs408","journal-title":"Eur Heart J"},{"key":"144_CR27","volume-title":"Br J Clin Pharmacol","author":"W Mueck","year":"2013","unstructured":"Mueck W, Kubitza D, Becka M: Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013. 10.1111\/bcp.12075"},{"key":"144_CR28","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1124\/dmd.108.025569","volume":"37","author":"C Weinz","year":"2009","unstructured":"Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D: Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos 2009, 37: 1056\u20131064. 10.1124\/dmd.108.025569","journal-title":"Drug Metab Dispos"},{"key":"144_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/0091270006296058","volume":"47","author":"D Kubitza","year":"2007","unstructured":"Kubitza D, Becka M, Zuehlsdorf M, Mueck W: Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59\u20137939) in healthy subjects. J Clin Pharmacol 2007, 47: 218\u2013226. 10.1177\/0091270006296058","journal-title":"J Clin Pharmacol"},{"key":"144_CR30","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1185\/03007990802361499","volume":"24","author":"D Kubitza","year":"2008","unstructured":"Kubitza D, Becka M, Roth A, Mueck W: Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008, 24: 2757\u20132765. 10.1185\/03007990802361499","journal-title":"Curr Med Res Opin"},{"key":"144_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1160\/TH09-03-0196","volume":"103","author":"J Jiang","year":"2010","unstructured":"Jiang J, Hu Y, Zhang J, Yang J, Mueck W, Kubitza D, Bauer RJ, Meng L, Hu P: Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban \u2013 an oral, direct factor Xa inhibitor \u2013 in elderly Chinese subjects. Thromb Haemost 2010, 103: 234\u2013241.","journal-title":"Thromb Haemost"},{"key":"144_CR32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/jcph.5","volume":"53","author":"D Kubitza","year":"2013","unstructured":"Kubitza D, Becka M, Roth A, Mueck W: The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban \u2013 an oral, direct factor Xa inhibitor. J Clin Pharmacol 2013, 53: 249\u2013255. 10.1002\/jcph.5","journal-title":"J Clin Pharmacol"},{"key":"144_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1365-2125.2009.03390.x","volume":"68","author":"X Zhao","year":"2009","unstructured":"Zhao X, Sun P, Zhou Y, Liu Y, Zhang H, Mueck W, Kubitza D, Bauer RJ, Zhang H, Cui Y: Safety, pharmacokinetics and pharmacodynamics of single\/multiple doses of the oral, direct factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol 2009, 68: 77\u201388. 10.1111\/j.1365-2125.2009.03390.x","journal-title":"Br J Clin Pharmacol"},{"key":"144_CR34","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/00498250500250493","volume":"35","author":"C Weinz","year":"2005","unstructured":"Weinz C, Buetehorn U, Daehler HP, Kohlsdorfer C, Pleiss U, Sandmann S, Schlemmer KH, Schwarz T, Steinke W: Pharmacokinetics of BAY 59\u20137939 \u2013 an oral, direct factor Xa inhibitor \u2013 in rats and dogs. Xenobiotica 2005, 35: 891\u2013910. 10.1080\/00498250500250493","journal-title":"Xenobiotica"},{"key":"144_CR35","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/clc.22037","volume":"35","author":"WF Peacock","year":"2012","unstructured":"Peacock WF, Gearhart MM, Mills RM: Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol 2012, 35: 730\u2013737. 10.1002\/clc.22037","journal-title":"Clin Cardiol"},{"key":"144_CR36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/FTD.0b013e3181f2f264","volume":"32","author":"E Lindhoff-Last","year":"2010","unstructured":"Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE: Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010, 32: 673\u2013679. 10.1097\/FTD.0b013e3181f2f264","journal-title":"Ther Drug Monit"},{"key":"144_CR37","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1160\/TH12-03-0209","volume":"108","author":"AGG Turpie","year":"2012","unstructured":"Turpie AGG, Kreutz R, Llau J, Norrving B, Haas S: Management consensus guidance for the use of rivaroxaban \u2013 an oral, direct factor Xa inhibitor. Thromb Haemost 2012, 108: 876\u2013886. 10.1160\/TH12-03-0209","journal-title":"Thromb Haemost"}],"container-title":["International Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1865-1380-6-25.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1865-1380-6-25\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1865-1380-6-25.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T06:47:26Z","timestamp":1532587646000},"score":1,"resource":{"primary":{"URL":"https:\/\/intjem.biomedcentral.com\/articles\/10.1186\/1865-1380-6-25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,16]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["144"],"URL":"https:\/\/doi.org\/10.1186\/1865-1380-6-25","relation":{},"ISSN":["1865-1380"],"issn-type":[{"value":"1865-1380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,16]]},"article-number":"25"}}